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Abstract 
 
The aim of this work is to analyze the metabolic 
pathways of Trypanosoma brucei and identify 
essential reactions that may be considered as drug 
targets. Data from the metabolic reaction database of 
TrypanoCyc version10.0.0 was used to establish a 
connected graph. The analysis of the biochemical 
network is based on its topology. The metabolic 
network was implemented with Perl. Two reactions 
were defined as neighbours if a metabolite that is the 
product of one reaction and substrate of the other 
exists. This yielded a bipartite graph of alternating 
reaction and metabolic compound nodes. A graph 
based algorithms were used to analyze the structure 
of the biochemical networks to infer differences when 
exposed to changing nutrient and environmental 
conditions. Choke-points and load-points were used 
to estimate if reactions are essential for the 
organism. This produced a network of 809 
metabolites and 798 reactions. With this strategy, we 
have identified 99 essential enzymatic reactions. 
These reactions can serve as drug targets to inhibit a 
normal metabolic flow in the parasite without 
harming the host. Further work is required to design 
drugs that can inhibit the targets. 
 
Introduction 
Human African trypanosomiasis (HAT), also known 
as sleeping sickness [1], is caused by species of 
Trypanosoma brucei. There are two forms of the 
disease: the acute form caused by Trypanosoma 
brucei rhodesiense which occurs mainly in East 
Africa and the chronic form caused by Trypanosoma 
brucei gambiense which arises mainly in West and 
Central Africa. Although their clinical infections 
differ in presentation and prognosis [2], the two 
protozoan parasites have identical morphologic 
appearances and are transmitted by tsetse fly. WHO 
estimates that up to 500,000 individuals are currently 
suffering from human trypanosomiasis in Africa, most 
of who are infected by Trypanosoma brucei 
gambiense [3]. 
There have been three severe epidemics of HAT over 
the last century: one between 1896 and 1906, mostly 
in Uganda and the Congo Basin, one in 1920 in 
several African countries and the one that began in 
1970 and is still in progress. The 1920 epidemic was 
arrested using mobile teams which systematically 
screened millions of ‘at-risk’ individuals. The disease 
practically disappeared between 1960 and 1965, but 
reappeared in several foci in the 1970s due to relaxed 
screening and lack of effective surveillance [4]. The 
resurgence has been attributed to civil wars, 
population movements, economic decline, reduced 
health financing, and lack of human resources in these 
areas [5-7]. Today, HAT occurs in 36 sub-Saharan 
countries within the distribution of the tsetse fly. 
There are about 250 foci of disease transmission and 
over 60 million people are at risk of contracting the 
disease [8]. There is no vaccine for HAT yet, and the 
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few drugs available are becoming ineffective due to 
parasite resistance. This underscores the need for new 
effective chemotherapeutic agents against the 
parasites.  
The delineation of the genome of T. brucei has raised 
the hope for new drug targets and vaccines [9]. 
Though several proteins have been identified as 
potential targets for drug treatment, T. brucei has over 
800 genes that code for proteins which the parasite 
mixes and matches to evade immune system 
detection; this makes the production of vaccines for 
the disease difficult [10]. Identification of novel drug 
targets is required to develop new classes of drugs in 
order to overcome drug resistance and replace less 
efficacious treatments. Analysis of metabolic 
pathways provides a useful conceptual framework for 
the identification of potential drug targets and also for 
improving our understanding of microbial responses 
to nutritional, chemical and other environmental 
stresses. A number of metabolic databases are 
available as tools for such analyses. In this work, data 
from the metabolic reaction database of TrypanoCyc 
version10.0.0 [11] was used to identify reactions 
which can serve as drug targets by inhibiting a normal 
metabolic flow in the parasite without harming the 
host.  
 
Material and Methods 
 
Metabolic Network Construction 
Data from the metabolic reactions database of 
TrypanoCyc version10.0.0. [11] was used for the 
analysis. A connected graph was established by 
defining neighbours of reactions: two reactions are 
neighbours if a metabolite that is the product of one 
reaction and the substrate for the other exists. This 
yields a bipartite graph of alternating reaction and 
metabolic compound nodes. A description of 
metabolic network is given in equation 1-4 and figure 
1a and 1b. Metabolites that were highly connected 
and therefore pathway unspecific, such as water, 
oxygen and ATP, were discarded. The metabolic 
network was implemented with Perl.  
Topology Analysis to Identify Essential Reactions 
We analyzed the biochemical network of 
Trypanosoma brucei based on its topology. A graph 
based algorithms of analysing the structure of 
biochemical networks was employed to infer 
differences when exposed to changing nutrients and 
environmental conditions and Reaction without 
deviation (RWD) analysis was used to identify 
potential drug targets [12]. The strategy was used to 
test the reactions coming out of the gene expression 
analysis on serving as crucial choke and load points 
for the organism while being harmless to the human. 
These reactions can serve as drug targets to inhibit a 
normal metabolic flow in the parasite without 
harming the host. Furthermore, concepts of choke-
points and load-points were used to estimate if 
reactions are essential for the organism [12, 13]. 
Choke-points basically and uniquely consume or 
produce a certain metabolite which may make them 
indispensable. It could be shown that inactivating 
choke-points lead to an organism’s failure. With a 
choke-point analysis [13], enzymes catalyzing choke-
point reactions were identified; each enzyme was 
assumed to have only one active site, unless 
annotated as multifunctional. If an enzyme catalyzed 
at least one choke-point reaction, it was classified as a 
potential drug target. The two concepts, RWD and 
choke-points, were implemented. 
   
Drug Targets in African Trypanosomes 
Several possible targets which could be exploited for 
the development of new drugs against African 
trypanosomiasis have been identified. Some drug 
targets against HAT are available at the TDR Targets 
Database [14]. The website aims to capture, collate 
and make public available expert knowledge on 
potential drug targets against parasitic diseases. Fifty 
of such targets are listed in Table 1.   
Given a set of reactions in a pathway:  
                                                 ZWF 
• R1: 1 G6P + 1 NADP   => 1 6PGL + 1 NADPH   ………………………..equation 1 
          PGL 
• R2: 1 6PGL + 1 H20    => 1 6PG   ……………………….. equation 2 
         GND 
• R3: 1 6PGL + 1 H2O   => 1 R5P + 1 NADPH   ……………………….. equation 3 
          RPE 
• R4: 1 R5P                    => 1 X5P   ………………………..equation 4
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Figure 1a: Substrate graph           Figure 1b: Reaction graph 
 
 
 
Table 1: Drug Targets against African Trypanosomes 
S/N EC Number  Enzyme Source Database / 
ID: 
Target Name 
1.  EC 2.7.1.67 Phosphatidylinositol 4-kinase Tb927.4.1140  Phosphatidyl-inositol 
2.  EC 6.3.2.2 Gamma-glutamylcysteine synthetase  Tb10.389.1360 Glutamate-cysteine 
3. EC 4.1.1.50 S-adenosylmethionine decarboxylase 
proenzyme 
GeneDB / 
Tb927.6.4460 
 (AdoMetDC) 
4. EC 3.6.3.14 ATP synthase complex Tb927.3.1380; 
Tb927.7.7420. 
ATP synthase 
5. EC 2.7.1.37 cell division related protein kinase 2 
(CRK3:CYC6)  
Tb10.70.2210. CRK3 
6. EC 2.5.1.18 GPI:protein transamidase complex Tb10.61.3060 GPI8 
7. EC 6.3.4.2 Trypanosome CTP Synthetase Tb927.1.1240 Trypanosome CTP 
Synthetase 
8. EC 2.7.11.1 Casein kinase 1.2 Tb927.5.800; 
Tb927.5.790. 
CK1.2 
9. N/A Peroxin 14 (PEX14) Tb10.100.0130 PEX14 
10. N/A Peroxin 5 (PEX5) Tb927.5.1100. PEX5 
11. EC 2.7.1.40 Pyruvate kinase (PYK) Tb10.61.2680 PYK 
12. EC 5.4.2.1 Phosphoglycerate mutase (PGAM) Tb10.6k15.2620 PGAM 
13. EC 2.7.1.11 Phosphofructokinase (PFK) Tb927.3.3270 PFK 
14. EC 4.2.1.11 Enolase (ENO) Tb10.70.4740 ENO 
15. EC 4.1.2.13 Fructose-1,6-bisphosphate aldolase 
(ALD) 
Tb10.70.1370 ALD 
16. EC 2.7.2.3 Phosphoglycerate kinase (PGK) Tb927.1.700. PGK-C or gPGK 
17. EC 1.1.1.49 Glucose-6-phosphate dehydrogenase 
(G6PDH) 
Tb10.70.5200 G6PDH 
18. N/A Vps34 Tb927.8.6210 TbVPS34 
19. EC 1.1.1.8 NAD-dependent glycerol-3-
phosphatedehydrogenase (NAD-GPDH) 
Tb927.8.3530 NAD-GPDH 
20. EC 5.3.1.9 Glucose-6-phosphate isomerase 
(phosphoglucose isomerase - PGI) 
Tb927.1.3830 PGI 
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21. EC 5.3.2.1 Triosephosphate isomerase (TIM) Tb11.02.3210 TIM 
22. EC 1.2.1.12 Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
Tb927.6.4280Tb92
7.6.4300 
gGAP 
23. N/A 5'-3' exonuclease (XRNA) Tb927.7.4900 XRNA 
24. N/A Pumilio domain protein (PUF9) Tb927.1.2600 PUF9 
25. N/A Small RNA binding proteins (UBP1 and 2 
) 
Tb11.03.0620Tb11
.03.0580 
UBP1 and 2 
26. N/A Nucleolar protein (DRBD1) Tb927.3.5280 DRBD1 
27. N/A Cyclin F box protein (CFB2) Tb927.1.4650 CFB2  
28. N/A MRNA degradation CAF1 deadenylase Tb927.6.600 CAF1 
29. N/A Alternative oxidase Tb10.6k15.3640 N/A 
30. EC 2.7.1.37 Glycogen synthase kinase (GSK) Tb10.61.3140 GSK 
31. N/A Aurora kinase 1 Tb11.01.0330 TbAUK1 
32. EC 4.1.1.17 Ornithine decarboxylase (ODC) Tb11.01.5300 ODC 
33. EC 2.7.1.- Polo-like kinase (PLK) Tb927.7.6310 PLK 
34. N/A Histone deacetylases (DAC1 and DAC3) Tb10.70.6220Tb92
7.2.2190 
DAC1 & DAC3 
35. EC 1.11.1.9 Non-selenium glutathione peroxidase 
(TbTPNI) 
Tb09.160.4250 
Tb09.160.4280 
TbTPNI 
36. EC 1.15.1.1 Superoxide dismutases (SODs) Tb11.01.7550Tb11
.01.6660 
TbSODB2 
37. EC 6.3.1.9 / 
EC 3.5.1.78 
trypanothione synthetase / amidase  Tb927.2.4370 trypanothione synthetase / 
amidase 
38. EC 1.8.1.12 Trypanothione reductase Tb927.2.4370 trypanothione reductase 
39. N/A Membrane-bound histidine acid 
phosphatase1 
Tb11.01.4701 TbMBAP1 
40. N/A Premature differentiation to the stumpy 
form.  
Tb927.6.4220 TbMAPK5 
41. EC 3.1.4.17 Cyclic nucleotide specific 
phosphodiesterases (PDEs) 
Tb09.160.3630 
Tb09.160.3590 
Phosphodiesterase 
42. EC 2.7.1.1 Hexokinase (HK) Tb10.70.5820 TbHK1 
43. N/A Metacaspases Tb927.6.940 MCA2 
44. EC 5.1.3.2 UDP-Glc 4'-Epimerase  UDP-Glc 4'-Epimerase 
45. N/A N-myristoyltransferase Tb10.61.2550 N-myristoyl transferase, 
46. EC 2.7.7.23 UDP-GlcNAc diphosphorylase Tb11.02.0120 UDP-GlcNAc 
diphosphorylase 
47. N/A Kinetoplatstid RNA editing ligase 1 Tb09.160.2970 Kinetoplatstid RNA editing 
ligase 
48. N/A Oligosaccharyl transferase (OST) N/A OST 
49. EC 2.5.1.58 Protein farnesyltransferase (PFT) Tb927.3.4490Tb92
7.7.460 
Protein farnesyltransferase 
50. EC 3.5.1.89 GlcNAc-PI de-N-acetylase Tb11.01.3900 GlcNAc-PI de-N-acetylase 
Targets lacking necessary information such as EC number (in red colour) were not considered in the analysis. 
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Results and Discussion 
 
A connected graph was established by defining neighbours 
of reactions yielded a bipartite graph of alternating reaction 
and metabolic compound nodes. This produced a network 
of 809 metabolites and 798 reactions. Each reaction was 
considered reversible since there was no contrary 
information available. Note that these reactions can serve as 
drug targets to inhibit a normal metabolic flow in the 
parasite without harming the host. With this strategy, we 
have identified 99 essential enzymatic reactions which can 
serve as drug targets (Table 2). 
In medical diagnostic test evaluation, more common metrics 
for evaluation are sensitivity and specificity. Sensitivity is 
the accuracy among positive instances and specificity 
among negative. Sensitivity and specificity overcome 
negative sides of accuracy (error type resolution and 
condition prevalence). Accuracy reflects the overall 
correctness of the classifier. 
 
Essential  6 93 99 
Non-essential  28 671 699 
Total   34 764 798 
 
Accuracy = 6+671/798 = 84.8%  
 
Sensitivity = 6/34 = 17.6% 
 
Specificity = 671/764 = 87.8% 
 
Precision = 6/6+93 = 6/99 = 6.06% 
 
Recall =   TP        = Sensitivity = True Positive Rate 
     TP + FN 
 
Precision =    TP 
       TP + FP 
 
A graph based algorithms of analysing the structure of 
biochemical networks to infer differences when exposed to 
changing nutrients and environmental conditions was 
employed for Plasmodium falciparum to test the reactions 
coming out of the gene expression analysis on serving as 
crucial choke and load points for the organism while being 
harmless to the human [12]. These reactions can serve as 
drug targets to inhibit a normal metabolic flow in the 
parasite without harming the host. Furthermore, concepts of 
choke-points and load-points were used to estimate if 
reactions are essential for the organisms [13]. Choke-points 
basically uniquely consume or produce a certain metabolite 
which may make them indispensable. It has been shown that 
inactivating choke-points lead to an organism’s failure. For 
example, in P. falciparum d-aminolevulinate dehydratase 
(ALAD) has been considered as such a choke-point [13]. 
With a choke-point analysis, 216 enzymes catalysing choke-
point reactions were identified P. falciparum [13]. Within 
the 216 identified potential targets, they identified three 
targets of clinically proven drugs and 24 proposed drug 
targets with biological evidence (such as in vitro growth 
inhibition of the parasite with target inhibition). Hence, with 
the combination of RWD and chokepoint analyses, we can 
confidently conclude that we have identified 99 essential 
enzymatic reactions which can serve as drug targets. 
 
Table 2:  Reaction without Deviation (RWD) and 
Chokepoint Analyses  
 
Method Essential reactions 
Reaction without Deviation 
(RWD) 
130 
Chokepoint 211 
Intercession (RWD and 
Chokepoint) 
99 
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